ClinicalTrials.gg
Not yet recruitingNCT06989567Updated May 29, 2025

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

A Phase 3 interventional study of L-citrulline and Placebo in Sickle Cell Disease, sponsored by Asklepion Pharmaceuticals, LLC. Not yet recruiting at 6 sites in United States. Open to participants aged 6 Years to 21 Years. Per ClinicalTrials.gov, last updated 2025-05-29.

Primary conditionVaso-Occlusive CrisesRegistry: Anemia, Sickle CellReclassifiedWhy we changed it
Registry
Anemia, Sickle Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Vaso-Occlusive Crises
Why
  1. The study's title name Vaso-Occlusive Crises, a narrower term within Anemia, Sickle Cell.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Asklepion Pharmaceuticals, LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
6 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Vaso-Occlusive Crises with a site in United States — 13 open to participants now, 15 under way, 5 of them phase 3. Vaso-Occlusive Crises · United States.

Planned enrollment
16th of 56
120 · median 63
Started
2025
with 1 other
Phase 3
17 of 60
3 open now
Primary completion
2027-06
later than 5 of 14 live
Registered
55th of 60
by date
Lead sponsor
2 of 60
Asklepion Pharmaceuticals, LLC

Among the 60 studies in Vaso-Occlusive Crises with a site in United States, this one is the 16th largest by planned enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2025, is one of 17 in phase 3, reaches primary completion later than 5 of the 14 other live ones, and was the 55th registered.

Vaso-Occlusive Crises

104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.

Browse Vaso-Occlusive Crises studies →

Open to participants now

13 of the 60 studies in Vaso-Occlusive Crises with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Vaso-Occlusive Crises studies recruiting now, 7 (41%) set no upper age limit and 6 (35%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 6 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Vaso-Occlusive Crises with a site in United States, or all of them as a file.
02

Study summary

This study is being done to learn more about a possible new treatment for pain episodes (called vaso-occlusive crises or VOCs) in children, teens, and young adults with sickle cell disease (SCD). The study will include about 120 participants between the ages of 6 and 21 who come to the emergency department (ED) with a VOC.

A VOC is a painful episode that happens with no clear cause and no signs of infection or major problems with organs like the liver or kidneys.

Before joining the study, patients and their families may be asked to learn about it and give permission (called consent or assent) while at a regular clinic visit. If that hasn't happened yet, the consent/assent process will happen at the emergency department when the patient comes in for care. If the patient meets all the study requirements, they can join the treatment part of the study.

Participants will be randomly assigned (like flipping a coin) to receive either:

L-citrulline, the study drug, or A placebo, which looks the same but has no active ingredients.

Everyone has an equal chance of getting either one. The study drug is given through an IV. It starts with one larger dose, followed by a steady infusion for up to 12 hours.

All patients in the study will still receive the usual pain treatment (called standard of care), which may include opioids. However, some patients may need fewer opioids if the study treatment helps with their pain.

If any medicines are not allowed during the study, the doctor will explain this during the consent process.

Patients can go home once:

Their pain is controlled with oral (by mouth) pain medicine, They're eating and drinking well, and They've been given a personal pain management plan to use at home.

After leaving the hospital, the study team will follow up with patients by phone about 2 days later (within a 12-hour window), again around Day 7, and again around Day 30 to check how they're doing.

Read the detailed description

What is Sickle Cell Disease (SCD)? Sickle cell disease is a genetic blood condition that affects red blood cells. People with SCD have a different kind of hemoglobin (called hemoglobin S) that can make red blood cells change shape. These sickle-shaped cells can block blood flow and cause painful episodes, organ damage, and other serious complications. In the U.S., about 100,000 people live with SCD, and it affects millions worldwide.

What is a VOC? A vaso-occlusive crisis (VOC) is one of the most common and painful problems in SCD. It happens when sickled red blood cells get stuck in small blood vessels, causing pain and damage. VOC is the main reason why people with SCD go to the emergency department or hospital.

Why is This Study Being Done? While there are medicines to help prevent VOCs, there are no treatments that work well to stop a VOC once it starts. That's what this study is trying to change. Researchers are testing L-citrulline, a natural substance found in the body and in some foods, to see if it can help stop a VOC in progress and reduce the need for pain medicine.

What is L-citrulline? L-citrulline is an amino acid that helps the body make nitric oxide, a substance that opens up blood vessels and improves blood flow. People with SCD often have low levels of nitric oxide, which can make VOCs worse. By giving L-citrulline through an IV, researchers hope to increase nitric oxide and relieve pain faster.

What Did Earlier Studies Show?

Earlier studies in children and teens with SCD showed that L-citrulline was:

Safe and well tolerated Most helpful at a specific dose (50 mg/kg followed by an infusion) Effective at reducing pain and lowering the need for opioid medications in some patients

The studies also showed that very high doses might not work as well. That's why the current study uses the best dose found in earlier research.

How Will This Study Work? This study will test how well L-citrulline works in the emergency room when a patient comes in with a VOC. Everyone in the study will still receive standard pain care, including opioids if needed. Some patients will also receive L-citrulline through an IV, and others will receive a placebo (a treatment that looks the same but has no active medicine). Researchers will compare how quickly the pain improves, how much medicine is needed, and how long patients stay in the hospital.

Is L-citrulline Safe? Yes, L-citrulline has been studied in many children, including those with heart conditions and SCD. It has not caused serious side effects in these studies. In fact, children with other medical problems safely take even higher doses. The most common side effect seen was temporary low blood pressure, which happened rarely and was not serious.

Why Is This Important? People with SCD deserve better options to treat pain quickly and safely. If this study shows that L-citrulline can help shorten or ease a VOC, it could lead to better care and fewer hospital stays in the future.

What is this study testing? This study is testing whether L-citrulline, given through an IV, can help treat a pain crisis (VOC) in people with sickle cell disease (SCD) more quickly and safely than standard treatment alone. The goal is to see if it reduces pain, lowers the need for pain medications like opioids, and shortens hospital stays.

Who can join?

The study includes:

Children, teens, and young adults ages 6 to 21 years Who come to the emergency department (ED) with a VOC Who do not have other causes of pain, serious infection, or organ problems

How does the study work? About 120 patients will take part in this study.

Each person will be randomly placed (like flipping a coin) into one of two groups:

One group gets L-citrulline The other group gets a placebo (a treatment that looks the same but has no active medicine) This process is double-blinded, meaning neither the patient nor the care team will know which treatment is being given.

What is the treatment? Patients receive a dose of the study drug (or placebo) within 2 hours of giving consent and before getting more IV pain medicine.

The treatment starts with a bolus dose (a quick push of medicine) followed by a continuous IV infusion for up to 12 hours.

All patients will still receive standard sickle cell pain care, but it may be adjusted depending on how well the study treatment works.

When can patients go home?

Patients may be discharged from the hospital once:

Their pain is controlled with oral pain medicine They are eating and drinking normally They have been given a personalized pain plan to manage symptoms at home

What happens after the hospital?

Patients will be followed by the study team:

At discharge About 2 days later Around Day 7 Around Day 30

Follow-up may happen by phone. The team will ask how the patient is feeling and whether they needed more care.

What will the researchers look at?

To understand how well the treatment works, the study will measure:

Pain scores How quickly the pain crisis gets better How much pain medication is used How long the hospital stay lasts How much pain interferes with daily life (using a short survey) Blood markers of inflammation and red blood cell damage

Who is watching the safety? An independent group of experts, including doctors and a statistician, will regularly review the study's progress and safety results. This group can recommend changes or even stop the study if needed to protect patients.

Why was this dose chosen?

Earlier studies in children with SCD showed that this dose of L-citrulline (50 mg/kg + 9 mg/kg/hr infusion) was:

Well tolerated (no serious side effects) Helpful in improving pain Safe, even at higher doses in other groups of children This dose was chosen based on those positive results.

When does a patient finish the study? A patient is considered to have finished the study once they complete the final visit (about 30 days after treatment).

When would the study stop early? A patient may be taken off the study if they have a serious or unexpected reaction that may be related to the treatment.

The whole study may be paused or stopped if two patients have serious reactions that the study doctor and sponsor believe may be related to the treatment.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

Keywords

  • sickle cell disease
  • citrulline
  • Vaso-Occlusive Crisis
  • Pain Crisis Relief in Sickle Cell Disease
  • Children and Adolescents with Sickle Cell
04

In context

Vaso-Occlusive Crises Reclassified

104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.

This study's planned enrollment of 120 is above the median of 81 across 86 interventional studies indexed under Vaso-Occlusive Crises.

Browse Vaso-Occlusive Crises studies →

Lead sponsor

Asklepion Pharmaceuticals, LLC is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Compared within Vaso-Occlusive Crises, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anemia, Sickle Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
6 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SCD (all genotypes)
  • Children, adolescents and young adults between ages 6 to 21 years
  • In a steady disease state and not in the midst of any acute complication other than VOC due to SCD at study entry
  • Baseline NRS score >5 or Faces Pain Scale score ≥6
  • For females of , a negative urine pregnancy test and using an adequate method of including abstinence
  • Patients or parents or legal guardian of the patient who are willing and able to sign and provide consent and assent (where appropriate for the age of the child)
  • Patients willing to begin study treatment within 120 minutes after providing /assent and soon after the first/initial dose, but before any subsequent doses of IV opioid or ketamine

Exclusion criteria

Exclusion Criteria:

  • Current pain lasting >3 days
  • History of 9 hospital admissions in the prior year
  • Participation in a clinical trial of a new therapy for SCD within the last 1 month
  • Presence of any other complication related to SCD such as splenic sequestration, hepatic sequestration, stroke, avascular necrosis of the hip/shoulder, acute priapism, acute renal dysfunction, acute chest syndrome and other major medical conditions or organ dysfunction
  • Hypotension requiring clinical intervention; hemodynamic instability; septic shock
  • Severe anemia ( \<6 g/dL)
  • Systemic therapy within the last 24 hours
  • Use of inhaled NO or medications that are known to cause hypotension (e.g., nitrates, sildenafil, tadalafil, vardenafil, osildenafil, or arginine) within the last 30 days
  • Serum creatinine levels:
  • Age 6-13 years: >0.9 mg/dL
  • Age 14-17 years: >1.0 mg/dL
  • Age ≥18 years: >1.5 mg/dL
  • Report of fever (>38°C) within the last 24 hours
  • Presence of acute chest syndrome, sepsis, known bacterial infection, or hemodynamic instability
  • Acute mental status or neurological changes
  • Acute stroke or clinical concern for stroke
  • Patients with inability to have assent given (ages 6 to 17 years) or consent (ages 18 through 21 years).

Note: Parents or legal guardians can provide consent for patients who are unable to provide assent (e.g., sleepy or preoccupied by their pain).

  • History of allergic reaction to L-citrulline product or dextrose
  • Unreliable venous access
  • The PI considers that the patient will be unable to comply with the study requirements
  • Patients pre-planned for admission on arrival in ED
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Participants randomized to this arm will receive a placebo intravenous (IV) treatment designed to match the appearance and administration schedule of L-citrulline. The placebo will be given as a single bolus dose followed by a continuous infusion for up to 12 hours. All participants will continue to receive standard of care pain management for sickle cell disease, consistent with the treating site's protocol and adjusted as needed based on the patient's clinical condition.

    Other: Placebo

  • Experimental
    L-citrulline Intravenous Treatment Arm

    Participants randomized to this arm will receive intravenous (IV) L-citrulline, a naturally occurring amino acid being investigated for its potential to treat vaso-occlusive crises (VOCs) in sickle cell disease. The study drug will be administered as a 50 mg/kg IV bolus, followed by a continuous infusion at 9 mg/kg/hour for up to 12 hours. The investigational product is provided as an isotonic solution in vials containing L-citrulline 50 mg/mL. Treatment will begin within 120 minutes of informed consent/assent and following the initial dose of opioid or ketamine, but prior to any subsequent doses. All participants will continue to receive standard-of-care (SoC) pain management per site protocol, which may be adjusted based on clinical response to study treatment.

    Drug: L-citrulline

Interventions

  • This intervention uses intravenous L-citrulline as an acute treatment for vaso-occlusive crisis (VOC) in sickle cell disease, administered as a 50 mg/kg IV bolus followed by a 9 mg/kg/hr continuous infusion. Unlike other studies that evaluate oral citrulline or chronic VOC prevention, this study focuses on real-time symptom resolution in the emergency department setting by targeting impaired nitric oxide production and vasoconstriction. The selected dosing regimen was optimized in prior studies to achieve a therapeutic plasma concentration associated with improved pain scores and reduced opioid use, distinguishing it mechanistically and clinically from other interventions.

  • OtherPlacebo

    Placebo intravenous (IV) treatment designed to match the appearance and administration schedule of L-citrulline

07

What researchers measure

Primary outcomes

  1. Change in pain score from baseline to discharge

    This outcome measures the change in self-reported pain using either the Numeric Rating Scale (NRS) or the Faces Pain Scale. Participants will rate their pain at baseline (prior to study treatment) and again at the time of hospital discharge. The pain scale used depends on the participant's age and cognitive ability. A clinically meaningful improvement is defined as a reduction of ≥2 points or ≥30% from baseline.

    Time frame: From enrollment to hospital discharge (typically within 12 to 72 hours), up to max of 30 day study duration

  2. Time to pain crisis resolution

    Time (in hours) from administration of the initial bolus dose of study drug (L-citrulline or placebo) to the end of the last IV opioid dose required during the hospitalization. This endpoint reflects how quickly the participant's vaso-occlusive crisis resolves to a degree that no longer requires intravenous opioid pain medication.

    Time frame: From start of study drug infusion to discontinuation of IV opioids (within the index hospitalization), up to max of 30 day study duration

Secondary outcomes

  1. Duration of hospital stay

    Measured in hours from the time of initial bolus dose of study drug (L-citrulline or placebo) to the time the discharge order is written. This outcome assesses how long participants remain hospitalized after receiving study treatment.

    Time frame: From study drug administration to hospital discharge (typically within 12 to 72 hours), up to max of 30 day study duration up to max of 30 day study duration

  2. Total opioid use during hospitalization

    The total amount of opioids administered (converted to morphine-equivalent dose in mg/kg) from emergency department (ED) registration until the discharge order is written.

    Time frame: From ED registration to hospital discharge, up to max of 30 day study duration

  3. Proportion of patients with ≥30% reduction in opioid use

    The percentage of patients whose total opioid dose over the course of hospitalization was reduced by 30% or more compared to the dose given prior to study treatment.

    Time frame: From start of study drug administration to hospital discharge, up to max of 30 day study duration

  4. Change in Patient-Reported Outcomes Measurement Information System Pain Interference Score

    Assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form, which measures how pain affects a participant's ability to engage in daily activities on a scale from 1 to 5, with lower scores indicating lower pain interference. The change is calculated from baseline to Day 7 (+2).

    Time frame: From baseline to Day 7 (+2) post-enrollment

  5. Hospital admission rate

    The percentage of participants admitted as in-patients due to sickle cell disease or complications related to vaso-occlusive crisis (VOC).

    Time frame: From ED presentation through hospital discharge or decision not to admit, up to max of 30 day study duration

Other outcomes

  1. Healthcare resource utilization

    This outcome measures differences in healthcare resource use between treatment groups, such as the number and duration of hospital admissions, procedures, and other health system interactions related to managing vaso-occlusive crisis (VOC). The analysis may include indirect estimates of healthcare savings associated with reduced admissions or shorter hospital stays.

    Time frame: From emergency department (ED) presentation through hospital discharge, up to max of 30 day study duration

  2. Cost utility and cost benefit

    This outcome evaluates the cost-effectiveness of L-citrulline versus placebo by examining costs in relation to health benefits, including quality of life. Analyses will incorporate changes in pain resolution time (pain measured using the Numeric Rating Scale (NRS) or the Faces Pain Scale) and use quality-adjusted life year (QALY) models (measured in QALY units) where applicable. Monetary valuation of hospital utilities may also be used for modeling financial impact. Composite results will be reported as a correlation between cost and effectiveness.

    Time frame: From ED presentation through Day 30 follow-up

  3. Change from baseline in hemoglobin concentration

    This outcome assesses the change in hemoglobin concentration (g/dL) as a biomarker of hemolysis. An increase in hemoglobin levels may indicate reduced hemolysis and improved disease status.

    Time frame: From baseline to discharge and at 48 hours post-bolus dose

  4. Change from baseline in serum bilirubin concentration

    This outcome evaluates the change in serum bilirubin (mg/dL), a marker of red blood cell breakdown and liver function. Decreased levels may indicate reduced hemolysis.

    Time frame: From baseline to discharge and at 48 hours post-bolus dose

  5. Change from baseline in lactate dehydrogenase (LDH) levels

    This outcome evaluates the change in LDH levels (mg/dL), an indicator of cell turnover and hemolysis. A reduction in LDH may correlate with reduced disease activity.

    Time frame: From baseline to discharge and at 48 hours post-bolus dose

  6. Change from baseline in reticulocyte count

    This outcome measures the change in reticulocyte count (10\^9/L) to evaluate bone marrow response to hemolysis. A decrease may indicate treatment effectiveness in reducing red blood cell destruction.

    Time frame: From baseline to discharge and at 48 hours post-bolus dose

  7. Change from baseline in C-reactive protein (CRP) concentration

    This outcome measures CRP levels (mg/L) as a marker of systemic inflammation. Decreased CRP may reflect reduced inflammatory activity associated with treatment.

    Time frame: From baseline to discharge and at 48 hours post-bolus dose

  8. Maximum Plasma Concentration (Cmax) of L-citrulline

    This outcome measures the peak plasma concentration (Cmax) of L-citrulline following dosing. Cmax will be used in subsequent analyses to evaluate pharmacokinetic-pharmacodynamic relationships with clinical outcomes like symptom improvement (e.g., pain reduction or time to crisis resolution). Data will help define therapeutic exposure ranges.

    Time frame: From time of first dose through 6 hours post-dose, with additional samples collected at discharge or as needed, up to max of 30 day study duration

  9. Area Under the Plasma Concentration-Time Curve (AUC) for L-citrulline

    This outcome measures AUC, a marker of overall L-citrulline exposure over time. AUC values will be evaluated in relation to clinical endpoints such as symptom improvement and time to crisis resolution. Data will help define therapeutic exposure ranges.

    Time frame: From time of first dose through 6 hours post-dose, with additional samples collected at discharge or as needed, up to max of 30 day study duration

  10. Steady-State Plasma Concentration (Css) of L-citrulline

    This outcome measures steady-state plasma concentration (Css) of L-citrulline when achieved during the study. Css will define therapeutic exposure ranges.

    Time frame: From time of first dose through 6 hours post-dose, with additional samples collected at discharge or as needed, up to max of 30 day study duration

08

Study locations

6 sites
09

References and documents

Publications

  • Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991 Jul 4;325(1):11-6. doi: 10.1056/NEJM199107043250103. PubMed 1710777 ↗
  • Davis H, Gergen PJ, Moore RM Jr. Geographic differences in mortality of young children with sickle cell disease in the United States. Public Health Rep. 1997 Jan-Feb;112(1):52-8. PubMed 9018289 ↗
  • Sundd P, Gladwin MT, Novelli EM. Pathophysiology of Sickle Cell Disease. Annu Rev Pathol. 2019 Jan 24;14:263-292. doi: 10.1146/annurev-pathmechdis-012418-012838. Epub 2018 Oct 17. PubMed 30332562 ↗
  • Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med. 2018 Jul 19;379(3):226-235. doi: 10.1056/NEJMoa1715971. PubMed 30021096 ↗
  • Barak M, Hu C, Matthews A, Fortenberry YM. Current and Future Therapeutics for Treating Patients with Sickle Cell Disease. Cells. 2024 May 16;13(10):848. doi: 10.3390/cells13100848. PubMed 38786070 ↗
  • Niihara Y, Zerez CR, Akiyama DS, Tanaka KR. Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol. 1998 Jun;58(2):117-21. doi: 10.1002/(sici)1096-8652(199806)58:23.0.co;2-v. PubMed 9625578 ↗
  • Brandow AM, Panepinto JA. Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Rev Hematol. 2010 Jun;3(3):255-60. doi: 10.1586/ehm.10.22. No abstract available. PubMed 21082977 ↗
  • Lanzkron S, Carroll CP, Haywood C Jr. The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database. Am J Hematol. 2010 Oct;85(10):797-9. doi: 10.1002/ajh.21807. PubMed 20730795 ↗
  • Sickle cell disease: managing acute painful episodes in hospital: Clinical guideline. London: National Institute for Health and Care Excellence (NICE); 2012 Jun 27. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK612041/ PubMed 39946515 ↗
  • Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010 Apr;38(4 Suppl):S512-21. doi: 10.1016/j.amepre.2009.12.022. PubMed 20331952 ↗
  • Ansong D, Akoto AO, Ocloo D, Ohene-Frempong K. Sickle cell disease: management options and challenges in developing countries. Mediterr J Hematol Infect Dis. 2013 Nov 4;5(1):e2013062. doi: 10.4084/MJHID.2013.062. eCollection 2013. PubMed 24363877 ↗
  • Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore). 2005 Nov;84(6):363-376. doi: 10.1097/01.md.0000189089.45003.52. PubMed 16267411 ↗
  • Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017 Apr 20;376(16):1561-1573. doi: 10.1056/NEJMra1510865. No abstract available. PubMed 28423290 ↗

Individual participant data

Plan to share: No — The study protocol does not specify plans to share individual participant data outside of the sponsor and authorized research team members.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2025; primary completion for Jun 2027, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 25, 2025
StartEst.
Jul 25, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2029
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06989567
Lead sponsor
Asklepion Pharmaceuticals, LLC
Responsible party
Sponsor
First posted
May 25, 2025
Start date
Jul 25, 2025 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2029 (estimated)
Last update
May 29, 2025

Study contacts

Gurdyal Kalsi, MD, MFPM (Hon)
Contact
gurdyal.kalsi@asklepionpharm.com
+1 410-736-3750
Heather Hill, BS
Contact
heather.hill@asklepionpharm.com
+1 443-691-2474
Suvankar Majumdar, MD
principal investigator · Center for Cancer and Blood Disorders, Children's National Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Citrulline

Start the discussion